Charles Lafitte Foundation Pledges $1 Million to the American Cancer Society's ... ( BRIELLE N.J. Feb. 19 -- The Char...)

Charles Lafitte Foundation Pledges $1 Million to the American Cancer Society's Hope Lodge

Date:2/19/2008

BRIELLE, N.J., Feb. 19 /PRNewswire-USNewswire/ -- The Charles Lafitte Foundation (http://www.charleslafitte.org), a philanthropic organization committed to providing support for education, children's advocacy, medical research and issues and the arts, today announced that it has pledged $1 million to the American Cancer Society's Manhattan Hope Lodge, which will provide free, temporary housing for cancer patients who are undergoing treatment at facilities in New York.

"The Hope Lodge facilities play a vital role in helping cancer patients and their caregivers deal with the emotional and financial burdens that are associated with a cancer diagnosis," said Suzanne Citron, Co-Founder of The Charles Lafitte Foundation. "Our foundation exists to help better the lives of others and we are confident that our gift will enable the American Cancer Society to continue to provide housing and services to more patients and their families who must frequently travel distances for necessary cancer treatments."

The American Cancer Society has created nearly thirty Hope Lodge facilities across the United States, offering patients much more than a place to stay while undergoing cancer treatments. The Manhattan Hope Lodge, located at West 32nd Street, is currently receiving guests and will offer the warmth and security of home as well as educational services for patients and caregivers and a 24-hour toll-free call center and web site with comprehensive on-site libraries, providing families with the information to help them make informed medical decisions. The facility will also serve as a community center for patient support groups and cancer initiatives. The Charles Lafitte Foundation's donation will be provided in five yearly installments of $200,000 per year.

"Both Suzanne and I were immediately attracted to the American Cancer Society's Hope Lodge because not only do the facilities fulfill an immed
'/>"/>

SOURCE Charles Lafitte Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Charles A. Peck, M.D., F.A.C.P. Joins LifeMasters as New Medical Director Focused on Client Experience
2. Ocular Pharma Company Charlesson Announces $2.35MM in New Funding
3. Charles S. Cohen, Pacific Design Center Augment Their Support for AIDS Walk Los Angeles
4. Charles Alan Launches Healthcare-focused Furniture Lines with NuBax Seating Technology, Offering Smart Design and Health Benefits
5. Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare
6. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
7. Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU
8. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
9. National Patient Safety Foundation Partners with Vocera Communications
10. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
11. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare

Post Your Comments:

(Date:11/27/2009)...ov.27/PRNewswire-FirstCall/--TheGymboreeCorporatio...willpresentattheNASDAQOMX23rdInvestorProgram,which...esday,December2,2009,at11:45a.m.GMT. ,, Toliste...ationovertheInternet,pleaselogontowww.gymboree.com...storandMediaRelations"andthen"ConferenceCalls&...

(Date:11/27/2009)...INE,France,Nov.27/PRNewswire/--TeamGarmin-Slipstre...dtoethicalsportinganddevelopingthenextgenerationof...mGarmin-TransitionswiththeadditionofTransitionsOpt...world,sleadingmanufacturerofadaptiveeyewear,offeri...selectionofspectaclelensessuchasTransitionslensesa...

(Date:11/27/2009)... XenaCare Holdings has announced that it has be...n, one of the largest nonprofit organizations dedi...ation. , Delray Beach, FL...nc. (OTCBB: XCHO), a company specializing in the m...hcare products, has announced today that is has be...

(Date:11/27/2009)... unprecedented medical, economic burdens, study pr...ws) -- The number of people with diabetes in the U...5 years, a new study predicts. , That would bri...with the disease, up from 23.7 million today. , ,...th diabetes will triple, the study also warns, ris...

(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...

Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4 Health News:Diabetes Cases Expected to Double in 25 Years 2 Health News:Diabetes Cases Expected to Double in 25 Years 3 Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2 Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3

[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation [0] Diabetes Cases Expected to Double in 25 Years [0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend

..., May 7 Conseco, Inc. (NYSE: CNO ),today reporte...t a new quarterly sales record with an increase of...ieur said. "This performance included,an 11% incre...surance Group,s sales declined 21%, but specified ...

...is common in the aggressive form of the disease, r...althDay News) -- For the first time, a gene linked... has been identified, researchers report. , "This ...ldhood Cancer Research at The Children,s Hospital ...

...ON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), ...esented today at a major scientific meeting findin...NIV, a selective alpha-2A-agonist. This compound,...(ADHD)., The data demonstrated that INTUNIV showed...

...ct Examination Finds Serious Violations in Long-Te... Acting Insurance,Commissioner Joel Ario today ann...ich was necessary due to a pattern of consumer har...2.3 million fine and an additional $30,million in ...

....3 million fine, CARMEL, Ind., May 7 Conseco, In...g state insurance regulators and two of,its insura...(CSHI) Company,and Bankers Life and Casualty Compa...e claims practices and,procedures, complaint handl...

...y 7 Longer life expectancy, greater,interest in s...ccess are,all factors fueling growth in sales of o...ted $68.4 billion in 2007 sales, with a 3.9% CAGR ... BTC and Other Growth Trends, this market should e...

Conseco Reports First Quarter Results Gene Variation Linked to Neuroblastoma, a Childhood Cancer Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms Insurance Department Fines Conseco Under Pennsylvania-Led, Multi-State Agreement Conseco Reaches Settlement of Multistate Market Conduct Examination Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012

(Date:11/26/2009)...hAfrica,Nov.26/PRNewswire/--The2009Frost&Sulli...rmaceuticalMarketispresentedtoCiplaMedproSouthAfri...-bin/prnh/20081117/FSLOGO ) ,, FortheCompanyoft...kCiplaMedpro,sperformanceagainstkeycompetitors:gro...usinessprocesses,productsand/ortechnologiesandlead...

(Date:11/25/2009)....25/PRNewswire-FirstCall/--AmericanScientificResou...announcethattheyhaveopenedaregionalmarketingandpro...hasbeenabletosecurealocationabroad,providinganesse...tandfuturehealthandsafetyproductsforchildrenandadu...anyhousesinventoryinthestateofOhiowheretheywillals...

(Date:11/25/2009)....25/PRNewswire-FirstCall/--Hologic,Inc.(Hologicort...cturerandsupplierofpremiumdiagnostics,medicalimagi...ealthcareneedsofwomen,isusingtheannualmeetingofthe...PlaceinChicago,November29throughDecember3,2009tohi...osticmammographyworkstationsoftware. ,, TheHolo...

[0] Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market [0] American Scientific Resources Inc. Opens Shanghai Location [0] New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity

...of patients with multiple sclerosis, remained re...l FTY720,- New data demonstrate 89% of patients fr...used by MS - three years after starting treatment,...disability, affects 2.5 million people wo...latory filings planned before end of 2009 in US an...

...tes potential for once daily oral d...neration MEK inhibitor, RDEA436, to enter Phase 1 ...2008 -, SAN DIEGO, April 15 Ardea Biosciences, I... presented demonstrating the,potent activity and f...mitogen-activated ERK kinase (MEK) inhibitor famil...

Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 2 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 3 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 4

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

...ic protein produced and stored in somatotrophs in ...the pituitary into the bloodstream in a pulsatile ...c somatostatin (SS) and GH-releasing factor (GHRF)...rs to be regulated by somatostatin, while the ampl...

...ocorticoid produced by the human adrenal cortex. I...y to corticosteroid-binding globulin (CBG), with t...ts on specific intracellular receptors with effect...e function, glucose counter-regulation, vascular t...

...F-I or somatomedin C) is a 7.6 kDa peptide produce...gen of cellular proliferation, exerting its action...n the circulation, IGF-I is bound to IGF-binding p...ions of IGF-I by modulating the interaction of IGF...

Medicine Products:

Bioactive hGH ELISA Test Cortisol RIA Test IGF-I IRMA Test (With Extraction)IGF-I IRMA Test (Non-Extraction)

Charles Lafitte Foundation Pledges $1 Million to the American Cancer Society's ...( BRIELLE N.J. Feb. 19 -- The Char...),Health